About 

Inflexion is backing CNX Therapeutics to build a scaled European speciality pharmaceutical platform in central nervous system (CNS) and hospital medicines. Inflexion carved CNX out of US-based Sunovion Pharmaceuticals and reinvested in 2025.

CNX acquires established, off-patent medicines that large pharmaceutical companies no longer prioritise and keeps them available to patients across Europe. It was the first UK-based pharmaceutical company to achieve B Corp certification.

Value acceleration  

Inflexion’s carve-out and healthcare experience helped establish CNX as an independent company. CNX has since grown through a series of acquisitions: Synchrony Pharma in 2022;  CNS and hospital products from Eisai, Clinigen and Sanofi in 2023 and 2024; and Sativex, a cannabinoid-based treatment for spasticity in multiple sclerosis, from Jazz Pharmaceuticals in 2025.

The business is now focusing on further product acquisitions, launching CNX’s first value-added medicines, building a niche generics pipeline and expanding commercial capability across Europe. Inflexion is supporting CNX on M&A origination and execution and has helped strengthen its board and leadership team. Inflexion’s digital team has also worked with CNX on sales data automation and visualisation.

Podcast

From carve-out to pan-European platform with CNX Therapeutics

Card image.
0:00 0:00